Premium
Moclobemide (Ro 11‐1163) vs. clomipramine in the treatment of depression: A double‐blind multicenter study in Belgium
Author(s) -
Cattiez P. H.,
Dierick M.,
Troisfontaines B.,
van Audenrode L.,
Defleur J.,
Hermans W.,
Roelandts A.,
Stenier P.,
Wolfrum C.
Publication year - 1990
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430210406
Subject(s) - moclobemide , tolerability , clomipramine , clinical global impression , antidepressant , psychology , depression (economics) , medicine , anesthesia , psychiatry , adverse effect , alternative medicine , macroeconomics , pathology , economics , placebo , anxiety
A multicenter study to compare the antidepressant efficacy and the tolerance of moclobemide (Ro 11‐1163) to clomipramine was performed in parallel groups of patients with minor depression. The duration of the study was 6 weeks, with weekly assessments by means of Hamilton Scale of Depression (HRDS) and the Clinical Global Impression (CGI). The efficacy of moclobemide was found to be as good as that of clomipramine. The results for tolerability were possibly in favor of moclobemide. It was recommended that consumption of tyramine‐containing foods be kept to a minimum or avoided and no hypertensive crises were reported.